FLT3 and acute myeloid leukemia: An analysis of RCT data revealed that FLT3-ITD AML patients with all ELN cytogenetic risk groups might benefit from midostaurin, while another report about midostaurin reported an improved relapse rate in the intermediate risk group only.6,33 In this study, our results showed that sorafenib post-transplantation could improve survival of FLT3-ITD AML patients with both favorable and adverse risk, but did not in those with intermediate risk.